New Delhi, April 1 -- Glenmark Pharmaceuticals Ltd stock is about 9% below its 52-week high of Rs.2,297.90 seen on 11 March, amid better business recovery. Consolidated revenue in the December quarter (Q3FY26) increased 15% year-on-year to Rs.3,901 crore, while Ebitda margin expanded to 22% from 18%, reflecting better operating efficiency and product mix.

A fresh trigger is the launch of Glipiq (semaglutide) on 21 March, marking its entry into the fast-growing weight loss market. Glenmark appears well-positioned to benefit, primarily due to its pricing.

While global GLP-1 therapies cost Rs.15,000-30,000 per month, Glenmark's semaglutide is priced at Rs.1,300-1,800 per month. This sharp drop improves accessibility, thus boosting volumes....